28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details

臨床試験数 : 267 /  薬物数 : 241 - (DrugBank : 77) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 180

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05486481
(ClinicalTrials.gov)		April 1, 20231/8/2022Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE)A Multicenter Phase 1/2 Study of Venetoclax / Daratumumab / Dexamethasone for Previously Treated Systemic Light-Chain Amyloidosis Patients With Translocation (11;14) (ALTITUDE STUDY)AL Amyloidosis;Light Chain (AL) Amyloidosis;Systemic Light Chain DiseaseDrug: Venetoclax;Drug: Dexamethasone;Drug: DaratumumabSandy Wong, MDJanssen Pharmaceuticals;AbbVieNot yet recruiting18 YearsN/AAll78Phase 1/Phase 2United States
2NCT05451771
(ClinicalTrials.gov)		October 26, 20226/7/2022Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) AmyloidosisAn Open-label Phase I/II Trial of Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Systemic Light-Chain AmyloidosisAL AmyloidosisDrug: Venetoclax Oral Tablet, 200 mg;Device: FISH assay;Drug: Venetoclax Oral Tablet, 400 mg;Drug: Dexamethasone Oral, 10 mg;Drug: Dexamethasone Oral, 20 mg;Drug: Daratumumab Injection;Drug: Bendamustine;Drug: Pomalidomide;Drug: Ixazomib;Drug: Venetoclax MTD with DexamethasoneRajshekhar Chakraborty, MDGenentech, Inc.Recruiting18 YearsN/AAll53Phase 1/Phase 2United States
3NCT03000660
(ClinicalTrials.gov)		January 201712/12/2016Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL AmyloidosisA Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL AmyloidosisAL AmyloidosisDrug: Venetoclax;Drug: DexamethasoneTufts Medical CenterNULLTerminated18 YearsN/AAll3Phase 1United States